Symbols

CMMB

Chemomab·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 1

MACD Death Cross

Ample Liquidity

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CMMB

Chemomab Therapeutics Ltd.

A clinical-stage biotech company focused on innovative therapeutics for fibrotic and inflammatory diseases

Industry

Biological Technology

Established Date

09/22/2011

Listing Date

02/12/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.chemomab.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

Kiryat Atidim, Building 7, Tel Aviv 6158002, Israel

Business

Introduction

Chemomab Therapeutics Ltd., was incorporated in Israel on September 22, 2011 under the Israeli Companies Law. Chemomab is a clinical-stage biotechnology company dedicated to discovering and developing innovative therapies for fibrosis-related diseases with high unmet needs. Based on the unique and critical role of the soluble protein CCL 24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block the activity of CCL 24. CM-101 has the potential to treat a variety of serious and life-threatening inflammatory and fibrotic diseases and is currently in clinical development for orphan diseases, primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Company Financials

EPS

CMMB has released its 2025 Q2 earnings. EPS was reported at 0, versus the expected -0.01, beating expectations. The chart below visualizes how CMMB has performed over recent quarters, highlighting trends in earnings surprises.